×

Kura Oncology to Present at the Jefferies 2015 Global Healthcare Conference

LA JOLLA, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 2:40 p.m. GMT (6:40 a.m. PST) on Thursday, November 19, at the Jefferies 2015 Global Healthcare Conference in London. The conference will be held at The May Fair Hotel, London, UK.

A live audio webcast and replay will be available in the Investors section of Kura Oncology's corporate website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura's pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor that is currently in two Phase 2 clinical studies: the first study in patients with locally advanced solid tumors that carry HRAS mutations and the second study in patients with peripheral T-cell lymphoma. The company plans to initiate a third Phase 2 clinical study in patients with lower risk myelodysplastic syndromes in the first half of 2016. Kura's preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program.

Forward Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the potential utility of Kura Oncology's compounds and product candidates, and plans regarding future research and development. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura Oncology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 robert.uhl@westwicke.com CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 mark@canalecomm.com

Source:Kura Oncology